Bull
$28.44
Scenario price
$23.800
-0.219 (-0.92%)At close
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.
OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $24.50, which is well below the analyst price target of $29 set by BTIG, indicating a potential upside of 18.37%. Additionally, the company has shown a strong revenue growth of 15.4% year-over-year in Q2, with a gross margin of 74%, which reflects operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which highlights ongoing profitability challenges.
BTIG
$29
2026-08-20
BTIG
2026-08-20
Price Target
$29
Truist
$22
2026-08-05
Truist
2026-08-05
Price Target
$22
Truist
$17
2026-05-01
Truist
2026-05-01
Price Target
$17
Canaccord
$25
2026-04-24
Canaccord
2026-04-24
Price Target
$25
Truist
$20
2026-03-02
Truist
2026-03-02
Price Target
$20
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

OrthoPediatrics Receives FDA Clearance for New Pediatric Nailing System

National Physical Therapy Month: Innovative Companies Supporting Health

OrthoPediatrics Launches 3P Pediatric Hip System After Successful Limited Rollout

OrthoPediatrics Q2 2026 Earnings Highlights

OrthoPediatrics Q2 Earnings Beat Expectations with Revenue Growth
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $24.50, which is well below the analyst price target of $29 set by BTIG, indicating a potential upside of 18.37%. Additionally, the company has shown a strong revenue growth of 15.4% year-over-year in Q2, with a gross margin of 74%, which reflects operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which highlights ongoing profitability challenges.
4 analysts cover KIDS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.